During the last session, Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s traded shares were 62.31 million, with the beta value of the company hitting 1.30. At the end of the trading day, the stock’s price was $0.24, reflecting an intraday gain of 14.31% or $0.03. The 52-week high for the PCSA share is $3.10, that puts it down -1191.67 from that peak though still a striking 37.5% gain since the share price plummeted to a 52-week low of $0.15. The company’s market capitalization is $6.36M, and the average intraday trading volume over the past 10 days was 12.42 million shares, and the average trade volume was 17.81 million shares over the past three months.
Processa Pharmaceuticals Inc (PCSA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. PCSA has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Processa Pharmaceuticals Inc (NASDAQ:PCSA) trade information
Processa Pharmaceuticals Inc (PCSA) registered a 14.31% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 14.31% in intraday trading to $0.24, hitting a weekly high. The stock’s 5-day price performance is 21.40%, and it has moved by -19.23% in 30 days. Based on these gigs, the overall price performance for the year is -72.53%. The short interest in Processa Pharmaceuticals Inc (NASDAQ:PCSA) is 0.53 million shares and it means that shorts have 0.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 97.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $9 respectively. As a result, PCSA is trading at a discount of -3650.0% off the target high and -3650.0% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.65%. While earnings are projected to return 81.52% in 2025, the next five years will return 42.13% per annum.
PCSA Dividends
Processa Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s Major holders
Processa Pharmaceuticals Inc insiders own 11.60% of total outstanding shares while institutional holders control 9.05%, with the float percentage being 10.24%.
